Latest News

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on June 1, 2020 AgeX received a Deficiency Letter from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders equity of less than $

Source link

Related posts

STAT Plus: U.S. launching program to spur investment in AI for health care


Jewish Languages in Historical Perspective


Nutritional supplement can slow cancer growth and enhance effects of chemotherapy


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World